IFT20 Confers Paclitaxel Resistance by Triggering β-arrestin-1 to Modulate ASK1 Signaling in Breast Cancer.

Ni Qiu Huan Jin Lulu Cui Yong-Tao Zhan Hao-Ming Xia Ming Jiang Jie Zhou Hong-Ling Liang Xiang Ao Zhi-Min He Hong-Sheng Li

Published in: Molecular cancer research : MCR (2023)

IFT20 drives paclitaxel resistance through modulating ASK1 signaling and IFT20 may act as a potential molecular biomarker for predicting the response to paclitaxel therapeutic in breast cancer.

Keyphrases

chemotherapy induced
young adults
single molecule
climate change
breast cancer risk
childhood cancer